曹璐璐　樓曉佳　周莉莉　吳月丹　何亦紅

[關鍵詞] 谷維素;糖尿病周圍神經病變;踝肱功能評分;ADL評分

[中圖分類號] R587.2? ? ? ? ? [文獻標識碼] B? ? ? ? ? [文章編號] 1673-9701（2021）22-0098-04

Observation of the efficacy of oryzanol in patients with diabetic peripheral neuropathy

CAO Lulu? ?LOU Xiaojia? ?ZHOU Lili? ?WU Yuedan? ?HE Yihong

Department of Endocrinology， the People′s Hospital of Dongyang City in Zhejiang Province， Dongyang? ?322100， China

[Abstract] Objective To observe the efficacy of oryzanol in patients with diabetic peripheral neuropathy. Methods A total of 152 patients with diabetic peripheral neuropathy treated in our hospital from July 2019 to January 2020 were retrospective analyzed and divided into the study group （n=76） and the control group （n=76） according to different treatment methods. The control group was treated with conventional therapy， while the study group was treated with oryzanol on the basis of the control group. Changes VAS score， ankle brachial index and quality of life score， oxidative stress level， MCV and total effective rate were observed before and after treatment in the two groups. Results Before treatment， VAS score， ankle brachial index and ADL score showed no difference between the two groups（P>0.05）; oxidative stress level showed no difference between the two groups（P>0.05）; and SCV and NCV showed no statistical significance between the two groups（P>0.05）. After treatment， VAS score in the study group was lower than that in the control group，and the difference was statistically significant（P<0.05）; ankle brachial index and ADL score in the study group were higher than that in the control group，and the difference was statistically significant（P<0.05）; oxidative stress level in the study group was higher than that in the control group，and the difference was statistically significant（P<0.05）; the conduction velocity of SCV and NCV in the study group was higher than that of the control group， and the difference was statistically significant（P<0.05）; the total effective rate in the study group was 94.74%， which was higher than that of 80.26% in the control group， and the difference was statistically significant（P<0.05）. Conclusion Oryzanol in the treatment of patients with diabetic peripheral neuropathy can effectively improve their pain， quality of life and oxidative stress level， which is worthy of application.

[Key words] Oryzanol; Diabetes peripheral neuropathy; Ankle brachial index; ADL score